Efficacy of Vortioxetine on the Physical Symptoms of Major Depressive Disorder
Overview
Affiliations
Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major depressive disorder (MDD), with broad beneficial effects on emotional, physical and cognitive symptoms. Limited specific data on the effects of vortioxetine on depression-related physical symptoms have been published.
Methods: A meta-analysis was carried out of five short-term multinational, double-blind, placebo-controlled studies. These studies were conducted in a total of 2105 adult MDD outpatients (18-75 years) with a major depressive episode of ⩾3 months' duration. Only patients treated with a dose of 5 or 10 mg vortioxetine (therapeutic doses) or placebo were included in this analysis. Efficacy assessment of vortioxetine on the physical symptoms of depression included all items of the Hamilton Depression Scale (HAM-D) assessing physical symptoms, and all somatic items in the Hamilton Anxiety Scale (HAM-A). A subgroup analysis in MDD patients with coexisting anxiety symptoms (i.e. those with a HAM-A ⩾20 at baseline) was also performed.
Results: A significant improvement ( p<0.05) of vortioxetine versus placebo was observed on all HAM-D items measuring physical symptoms, except for the somatic gastrointestinal symptoms and loss of weight items. Significant effects were also observed on the HAM-A somatic items: general somatic symptoms, gastrointestinal symptoms, and autonomic symptoms. In patients with a high baseline level of anxiety, a significant effect of vortioxetine was also observed on the physical symptoms of depression.
Conclusions: These analyses indicate that patients with MDD, including those with a high level of anxiety symptoms, have significant improvements in MDD-associated physical symptoms when treated with vortioxetine.
DelBello M, Findling R, Huss M, Necking O, Petersen M, Schmidt S Eur Child Adolesc Psychiatry. 2024; .
PMID: 39240359 DOI: 10.1007/s00787-024-02560-1.
Christensen M, Canellas F, Loft H, Montejo A Neuropsychiatr Dis Treat. 2024; 20:1475-1489.
PMID: 39100571 PMC: 11297586. DOI: 10.2147/NDT.S473056.
Di Nicola M, Adair M, Rieckmann A, Christensen M C J Psychopharmacol. 2024; 38(7):615-623.
PMID: 39077889 PMC: 11290038. DOI: 10.1177/02698811241260996.
Wang G, Si T, Rieckmann A, Ma J, Christensen M Neuropsychiatr Dis Treat. 2024; 20:1211-1223.
PMID: 38863483 PMC: 11166150. DOI: 10.2147/NDT.S460408.
Cuomo A, Aguglia A, de Berardis D, Ventriglio A, Gesi C, Fagiolini A Ann Gen Psychiatry. 2024; 23(1):20.
PMID: 38755657 PMC: 11097484. DOI: 10.1186/s12991-024-00505-1.